Binding Modes and Metabolism of Caffeine

Chem Res Toxicol. 2019 Jul 15;32(7):1374-1383. doi: 10.1021/acs.chemrestox.9b00030. Epub 2019 Jun 11.

Abstract

A correct estimate of ligand binding modes and a ratio of their occupancies is crucial for calculations of binding free energies. The newly developed method BLUES combines molecular dynamics with nonequilibrium candidate Monte Carlo. Nonequilibrium candidate Monte Carlo generates a plethora of possible binding modes and molecular dynamics enables the system to relax. We used BLUES to investigate binding modes of caffeine in the active site of its metabolizing enzyme Cytochrome P450 1A2 with the aim of elucidating metabolite-formation profiles at different concentrations. Because the activation energies of all sites of metabolism do not show a clear preference for one metabolite over the others, the orientations in the active site must play a key role. In simulations with caffeine located in a spacious pocket above the I-helix, it points N3 and N1 to the heme iron, whereas in simulations where caffeine is in close proximity to the heme N7 and C8 are preferably oriented toward the heme iron. We propose a mechanism where at low caffeine concentrations caffeine binds to the upper part of the active site, leading to formation of the main metabolite paraxanthine. On the other hand, at high concentrations two molecules are located in the active site, forcing one molecule into close proximity to the heme and yielding metabolites theophylline and trimethyluretic acid. Our results offer an explanation of previously published experimental results.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Caffeine / chemistry
  • Caffeine / metabolism*
  • Catalytic Domain
  • Cytochrome P-450 CYP1A2 / chemistry
  • Cytochrome P-450 CYP1A2 / metabolism*
  • Heme / chemistry
  • Humans
  • Ligands
  • Models, Chemical
  • Molecular Dynamics Simulation
  • Monte Carlo Method
  • Protein Binding

Substances

  • Ligands
  • Caffeine
  • Heme
  • Cytochrome P-450 CYP1A2